PE20040306A1 - THERAPEUTIC METHODS OF SAPOGENINS AND THEIR DERIVATIVES - Google Patents
THERAPEUTIC METHODS OF SAPOGENINS AND THEIR DERIVATIVESInfo
- Publication number
- PE20040306A1 PE20040306A1 PE2003000315A PE2003000315A PE20040306A1 PE 20040306 A1 PE20040306 A1 PE 20040306A1 PE 2003000315 A PE2003000315 A PE 2003000315A PE 2003000315 A PE2003000315 A PE 2003000315A PE 20040306 A1 PE20040306 A1 PE 20040306A1
- Authority
- PE
- Peru
- Prior art keywords
- derivatives
- therapeutic methods
- sapogenins
- cognitive
- neurodegeneration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Catalysts (AREA)
Abstract
The invention discloses therapeutic methods and uses of certain steroidal sapogenins, related compounds and derivatives thereof, in the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP020101170A AR033079A1 (en) | 2001-03-28 | 2002-03-27 | SAPOGENINE DERIVATIVES, SYNTHESIS AND USE, AND METHODS BASED ON USE |
US36817802P | 2002-03-28 | 2002-03-28 | |
PCT/GB2002/001578 WO2002079221A2 (en) | 2001-03-28 | 2002-03-28 | Sapogenin derivatives, their synthesis and use |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20040306A1 true PE20040306A1 (en) | 2004-05-29 |
Family
ID=30001210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2003000315A PE20040306A1 (en) | 2002-03-27 | 2003-03-27 | THERAPEUTIC METHODS OF SAPOGENINS AND THEIR DERIVATIVES |
Country Status (10)
Country | Link |
---|---|
KR (1) | KR20100093621A (en) |
CN (1) | CN1642558B (en) |
AT (1) | ATE424211T1 (en) |
IL (1) | IL164161A0 (en) |
NZ (2) | NZ547897A (en) |
PE (1) | PE20040306A1 (en) |
PL (1) | PL213697B1 (en) |
RU (1) | RU2332999C2 (en) |
TW (1) | TWI329016B (en) |
WO (1) | WO2003082893A2 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6861788B2 (en) * | 2003-06-03 | 2005-03-01 | Motorola, Inc. | Switchable display/mirror method and apparatus |
FR2868700B1 (en) * | 2004-04-09 | 2008-09-26 | Michel Coisy | USE OF DOPAMINE OR ITS BIOLOGICAL PRECURSORS AGAINST ALGONURODYSTRPHY. |
GB0409567D0 (en) | 2004-04-28 | 2004-06-02 | Phytopharm Plc | Chemical compounds |
GB0424528D0 (en) | 2004-11-05 | 2004-12-08 | Phytopharm Plc | Chemical compounds |
HUE035328T2 (en) | 2005-10-28 | 2018-05-02 | Univ Industry Cooperation Group Kyung Hee Univ | Extract of the family dioscoreaceae and composition for preventing or treating peripheral neuropathy comprising the same |
JP2012515754A (en) | 2009-01-24 | 2012-07-12 | ファイトファーム ピーエルシー | Treatment of neurotrophic factor mediated diseases |
CN103189056A (en) * | 2010-07-20 | 2013-07-03 | 植物药物公共有限公司 | Treatment of L-DOPA, dopamine agonist and/or dopamine enhancer induced disorders |
EP4245369A3 (en) | 2011-09-08 | 2023-11-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
CU20110244A7 (en) * | 2011-12-27 | 2013-08-29 | Ct De Investigación Y Desarrollo De Medicamentos Cidem | SPI-ESTEROID SYSTEMS WITH NEUROACTIVE AND ANTI-INFLAMMATORY EFFECTS |
US11319338B2 (en) | 2012-04-03 | 2022-05-03 | Goldporp Pharma Limited | Timosaponin compounds |
CN112375115A (en) | 2013-03-13 | 2021-02-19 | 萨奇治疗股份有限公司 | Neuroactive steroids and methods of use thereof |
CN103232520A (en) * | 2013-05-13 | 2013-08-07 | 中国药科大学 | Spirosteroid compounds and preparation method and medical application thereof |
ES2970222T3 (en) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxysterols and procedures for their use |
BR112018000129B1 (en) | 2015-07-06 | 2024-01-09 | Sage Therapeutics, Inc | Oxysterol compounds, their uses and pharmaceutical composition |
MA42409A (en) | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | OXYSTEROLS AND THEIR METHODS OF USE |
JP2018519328A (en) | 2015-07-06 | 2018-07-19 | セージ セラピューティクス, インコーポレイテッド | Oxysterols and methods of their use |
DK3436022T3 (en) | 2016-04-01 | 2022-06-20 | Sage Therapeutics Inc | OXYSTEROLS AND PROCEDURES FOR USE THEREOF |
WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
PL3481846T3 (en) | 2016-07-07 | 2021-12-20 | Sage Therapeutics, Inc. | 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions |
CN110023323A (en) | 2016-09-30 | 2019-07-16 | 萨奇治疗股份有限公司 | The oxygen sterol that C7 replaces and its method as NMDA regulator |
AU2017345399B2 (en) | 2016-10-18 | 2022-02-24 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
MX2019004578A (en) | 2016-10-18 | 2019-10-09 | Sage Therapeutics Inc | Oxysterols and methods of use thereof. |
CN108264535A (en) * | 2016-12-30 | 2018-07-10 | 中国科学院上海药物研究所 | A kind of antidepressant compounds and its preparation method and application |
RU2635485C1 (en) * | 2017-03-21 | 2017-11-13 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Method for optic nerve atrophy treatment after craniocerebral injury |
CN109988218B (en) * | 2017-12-29 | 2022-11-25 | 中国科学院上海药物研究所 | Sarsasapogenin derivative and preparation method and application thereof |
EP3572085A1 (en) * | 2018-05-25 | 2019-11-27 | Neuro-Sys | Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and optionnaly a second polyphenolic compound |
CN112457362B (en) * | 2019-09-06 | 2023-09-19 | 上海青东生物科技有限公司 | Halogenated tetracyclic triterpene derivative and preparation and application thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3416112A1 (en) * | 1984-04-30 | 1985-10-31 | Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen | USE OF STEROLINES AND SPIROKETALINES AS LIPOXYGENAS REGULATORS |
US4680289A (en) * | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
JPH05246866A (en) * | 1992-03-06 | 1993-09-24 | Ruibosuteii Japan:Kk | Agent for stimulating cerebral metabolism and for improving cerebral function |
DE4303214A1 (en) * | 1993-02-04 | 1994-08-11 | Wolfgang Marks | Treatment of diseases of viral, viroidal or oncogenic origin by steroid saponins or their aglycones |
TW479061B (en) * | 1993-12-24 | 2002-03-11 | Mitsubishi Chem Corp | Sialic acid derivatives |
JPH092957A (en) * | 1995-06-22 | 1997-01-07 | Mitsubishi Chem Corp | Therapeutic and preventing agent for peripheral neuropathy |
JPH092956A (en) * | 1995-06-22 | 1997-01-07 | Mitsubishi Chem Corp | Therapeutic and preventing agent for neuropathy |
US6046185A (en) * | 1996-07-11 | 2000-04-04 | Inflazyme Pharmaceuticals Ltd. | 6,7-oxygenated steroids and uses related thereto |
CN1131237C (en) * | 1997-09-26 | 2003-12-17 | 中国人民解放军军事医学科学院放射医学研究所 | Usage of steroi saponin for preventing and curing senile dementia and new steroid saponin |
GB9923076D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
BR9909109A (en) * | 1998-03-26 | 2000-12-12 | Phytopharm Plc | Uses of one or more among smilagenin, pleasedigenin, an astragaloside, tigogenin, ruscogenin, hecogenin, diogenin, smilagenin, anzurogenin d or an astragaloside and an extract from a plant of the genus smilax, asparagus, anemarrhena, yucca, yucca or yucca. for the treatment of a condition distinguished by a deficiency in the function or the number of membrane-bound postsynaptic receptors, pharmaceutical composition, and, processes to enhance cognitive function in a human or non-human animal and in a patient suffering from an age-related cognitive impairment, and to treat a condition distinguished by a deficiency in function or the number of membrane-bound receptors in a tissue, organ, cell type or organelle |
GB9923078D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
GB9923077D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
GB0000228D0 (en) * | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
JP2002030096A (en) * | 2000-07-11 | 2002-01-29 | Kyorin Pharmaceut Co Ltd | Agent for regenerating neurocyte process and method for producing the same |
EP1496913A4 (en) * | 2002-03-15 | 2007-10-31 | Samaritan Pharmaceuticals Inc | Neuroprotective spirostenol pharmaceutical compositions |
-
2003
- 2003-03-27 WO PCT/GB2003/001380 patent/WO2003082893A2/en active Application Filing
- 2003-03-27 NZ NZ547897A patent/NZ547897A/en unknown
- 2003-03-27 PE PE2003000315A patent/PE20040306A1/en not_active Application Discontinuation
- 2003-03-27 TW TW092106926A patent/TWI329016B/en not_active IP Right Cessation
- 2003-03-27 NZ NZ547344A patent/NZ547344A/en unknown
- 2003-03-27 RU RU2004130281/15A patent/RU2332999C2/en not_active IP Right Cessation
- 2003-03-27 IL IL16416103A patent/IL164161A0/en unknown
- 2003-03-27 AT AT03722713T patent/ATE424211T1/en active
- 2003-03-27 CN CN038071886A patent/CN1642558B/en not_active Expired - Fee Related
- 2003-03-27 PL PL372941A patent/PL213697B1/en not_active IP Right Cessation
- 2003-03-27 KR KR1020107017081A patent/KR20100093621A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CN1642558A (en) | 2005-07-20 |
RU2332999C2 (en) | 2008-09-10 |
TWI329016B (en) | 2010-08-21 |
PL213697B1 (en) | 2013-04-30 |
CN1642558B (en) | 2012-05-30 |
WO2003082893A2 (en) | 2003-10-09 |
WO2003082893A3 (en) | 2004-04-15 |
NZ547344A (en) | 2007-11-30 |
WO2003082893A8 (en) | 2003-12-31 |
RU2004130281A (en) | 2006-01-20 |
NZ547897A (en) | 2008-02-29 |
IL164161A0 (en) | 2005-12-18 |
TW200400042A (en) | 2004-01-01 |
PL372941A1 (en) | 2005-08-08 |
KR20100093621A (en) | 2010-08-25 |
ATE424211T1 (en) | 2009-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20040306A1 (en) | THERAPEUTIC METHODS OF SAPOGENINS AND THEIR DERIVATIVES | |
TR200700134T1 (en) | Derivatives of sapogenin, their synthesis and usage, methods of their use. | |
HK1046912A1 (en) | Substituted sapogenins and their use | |
HRP20080467A2 (en) | 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia | |
DK1719512T3 (en) | Sarsasapogenin and smilagenin for the treatment of cognitive dysfunction | |
TW200528117A (en) | Methods and reagents for the treatment of proliferative diseases | |
BR0309665A (en) | Treatment of alpha-galactosidase deficiency at | |
DE60108857D1 (en) | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ALPHA-ADRENEER RECEPTORS | |
EP2301625A3 (en) | Compositions and methods for treating cognitive disorders | |
WO2005000208A3 (en) | Combination therapy for the treatment of neoplasms | |
GB9923078D0 (en) | Sapogenin derivatives and their use | |
WO2004007531A3 (en) | Activated checkpoint therapy and methods of use thereof | |
TR200101149T2 (en) | Treatment of external retinal disorders. | |
HRP20041009A2 (en) | Theraputic methods and uses of sapogenins and their derivatives | |
TW200833344A (en) | Therapeutic methods and uses of sapogenins and their derivatives | |
UA85187C2 (en) | 2-aminobenzoyl derivatives | |
BR0308788A (en) | Therapeutic processes and uses of sapogenins and their derivatives | |
MY134920A (en) | 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia | |
WO2004073631A3 (en) | Combination therapy for the treatment of neoplasms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |